ACCESSIBILITY

24/7

Headlines

07:29

MSC denies interest in acquiring ZIM

21:50

Full list of Israeli startup M&As in 2025

21:48

Zendesk acquires AI search startup Unleash for tens of millions

21:03

As Intel stumbles, Nvidia emerges as Israel’s anchor tech employer

Buzz

Most popular

Daily

Weekly

Huang declares Israel Nvidia’s “second home” with record-breaking campus investment

Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal

Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation

Cyera raises $400 million at $9 billion valuation in Blackstone-led round

Zendesk acquires AI search startup Unleash for tens of millions

More news

Immunotherapy

9 stories about Immunotherapy

Cancer Immunotherapy Startup NeoTX Raises $45 Million

20.02.20|Adi Pick

NeoTX uses STR to bind genetically engineered bacteria to tumor cells and simultaneously activate the antibacterial response of distant immune cells

Allogenic Immunotherapy Company Adicet Bio Raises $80 Million

02.10.19|Meir Orbach

Founded by Israeli chemist Aya Jakobovits, Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

02.10.19|Tzally Greenberg

Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer

The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich

The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer

The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy

Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur

Cell Immunotherapy Company Raises $8 Million

24.09.17|Lilach Baumer

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in autoimmune and inflammatory conditions